• In the first quarter of 2026, Centene Corporation reported revenue of US$49.94 billion and net income of US$1.54 billion, with diluted EPS from continuing operations of US$3.11, all higher than a year earlier.
• Alongside these results, Centene raised its 2026 guidance, lifting expected total revenue to between US$187.50 billion and US$191.50 billion and increasing its GAAP diluted EPS outlook to above US$2.37, signaling management’s confidence in ongoing margin and cost initiatives.
• We’ll now examine how Centene’s upgraded full-year revenue and earnings guidance may influence its existing investment narrative and medium-term outlook.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Centene Investment Narrative Recap

To own Centene, you need to believe that a large, government-focused insurer can steadily improve margins while managing policy and medical cost uncertainty. The latest Q1 2026 beat and raised guidance support the near term catalyst of Medicaid margin recovery, but they do not remove the key risk that reimbursement rates and medical costs, including specialty drugs and seasonal illnesses, could still pressure profitability if conditions shift.

The most relevant recent development is Centene’s decision to lift its 2026 revenue outlook to US$187.50–191.50 billion and raise its GAAP diluted EPS floor to above US$2.37. This sits alongside earlier commentary about margin improvement in Medicaid and cost controls, suggesting that current guidance is anchored in operating progress, even as uncertainties around Medicaid rates and health care policy remain important watchpoints for the story.

Yet beneath the stronger guidance, investors should still pay attention to how rising regulatory scrutiny on Medicaid reimbursement could...

Centene's narrative projects $199.0 billion revenue and $2.8 billion earnings by 2029.

Uncover how Centene's forecasts yield a $43.47 fair value, a 21% downside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming revenue of about US$181.3 billion and earnings of only US$392.3 million by 2028, so their much weaker margin outlook contrasts sharply with the recent guidance upgrade and reminds you that opinions can differ widely and may shift again as new results and policy signals come through.

Explore 16 other fair value estimates on Centene - why the stock might be worth 42% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Centene research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Centene research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Centene's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.